Xencor to Examine Safety of Lymphoma Drug: "Xencor has begun a Phase I clinical trial with XmAb2513, a humanized monoclonal antibody that targets the antigen CD30, in patients with Hodgkin lymphoma and anaplastic large cell lymphoma.
The open-label, dose-escalation study will determine the recommended dose for subsequent trials, examine the drug’s safety and tolerability and characterize pharmacokinetics and immunogenicity."